Skip to content
value.today
ProMIS Neurosciences Inc. logo

ProMIS Neurosciences Inc.

Total raised
$34 M
4 rounds on record
Latest round
$7 M
Oct 2022
First round on record
Apr 2018
Today
Went public
See the company page

ProMIS Neurosciences Inc. is listed today as Promis Neurosciences Inc.: market value, financials and filings are on its company page.

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of ProMIS Neurosciences Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2022$7 MNo. 4$2 to $10 million

ProMIS Neurosciences Inc.: Raise no. 4, Oct 2022

Investors in this round

23 investors had bought by the notice of Oct 21, 2022: 23 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for ProMIS Neurosciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$7 M of $10 M offered; $3 M still to sell
Smallest investment taken
$27,000
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Each unit consists of one common share and one-quarter of one common share purchase warrant. Each full warrant is exercisable for one common share at an exercise price of $7.50 per common share starti
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
No revenue
Sales commissions
$597,783
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Canada (Federal Level)

People named in the notice

  • Daniel T. Geffken · Executive Officer
  • Gail M. Farfel · Executive Officer
  • Gavin T. Malenfant · Executive Officer
  • Larry M. Altstiel · Executive Officer
  • Neil M. Cashman · Executive Officer, Director
  • Eugene T. Williams · Director
  • Josh T. Mandel-Brehm · Director
  • Maggie T. Shafmaster · Director
  • Neil K. Warma · Director
  • Patrick T. Kirwin · Director
  • Richard T. Gregory · Director
  • William K. Wyman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • CEROS FINANCIAL SERVICES, INC. (CRD 37869) · Rockville, MarylandSold in CA, CO, FL, IL, MA, NH, NJ, NV, NY, TX, VA, VT

Remarks in the notice

  • On fees: “Compensation also includes warrants to purchase 69,188 common shares at $6.10 per share exercisable April 11, 2023 until April 11, 2028, and legal fees of $80,000.”
  • On the amounts: “The additional $2,594,541.00 may be received upon the exercise of share purchase warrants sold inside or outside the U.S.”
  • On the use of proceeds: “In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors.”

Signed by Gail M. Farfel, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 21, 2022. Read the notice at the SEC.

equity, optionsSEC
Aug 2021$18 MNo. 3$10 to $50 million

ProMIS Neurosciences Inc.: Raise no. 3, Aug 2021

Investors in this round

34 investors had bought by the notice of Sep 9, 2021: 34 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for ProMIS Neurosciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$18 M of $25 M offered; $7 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Each unit consists of one common share and one quarter of one common share purchase warrant. Each whole warrant is exercisable for one common share at an exercise price of $0.21 per common share until
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
No revenue
Sales commissions
$12,674,900
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Canada (Federal Level)

People named in the notice

  • Daniel Geffken · Executive Officer
  • Elliot Goldstein · Executive Officer
  • Eugene Williams · Executive Officer, Director
  • Johanne Kaplan · Executive Officer
  • Neil Cashman · Executive Officer, Director
  • Patrick Kirwin · Director
  • Richard Gregory · Director
  • William Wyman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Ceros Financial Services, Inc. (CRD 37869) · Rockville, MarylandSold in CA, FL, ID, IL, MA, NH, NJ, NV, NY, PA, TX

Remarks in the notice

  • On fees: “Includes 7,921,813 compensation warrants to purchase one common share of common stock at a price of $0.16 per share at any time for up to 5 years.”
  • On the amounts: “The additional $6,603,516.00 may be received upon the exercise of share purchase warrants sold inside or outside the U.S.”
  • On the use of proceeds: “In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors.”

Signed by Elliot Goldstein, Ceo. Source: SEC Form D, newest notice filed Sep 9, 2021. Read the notice at the SEC.

equity, optionsSEC
Mar 2021$7 MNo. 2$2 to $10 million

ProMIS Neurosciences Inc.: Raise no. 2, Mar 2021

Investors in this round

7 investors had bought by the notice of Mar 30, 2021: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for ProMIS Neurosciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
no minimum stated
What was sold
equity, debt, options or other rights to buy securities, securities to be acquired by exercising them, other: 1% convertible debentures, payable annually. The Convertible Debentures will mature on March 22, 2026 and are convertible into shares at US$0.10 per share.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Canada (Federal Level)

People named in the notice

  • Daniel E. Geffken · Executive Officer
  • Elliot Goldstein · Executive Officer, Director
  • Eugene Williams · Executive Officer, Director
  • Johanne Kaplan · Executive Officer
  • Neil Cashman · Executive Officer, Director
  • Steven Plotkin · Executive Officer
  • Patrick Kirwin · Director
  • Richard Gregory · Director
  • William Wyman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total Offering Amount represents principal amount of US$7,000,000 convertible debentures. There is no guarantee that the convertible debentures will be converted into shares.”

Signed by Elliot Goldstein, CEO and President. Source: SEC Form D, newest notice filed Mar 30, 2021. Read the notice at the SEC.

equity, debt, optionsSEC
Apr 2018$2 MNo. 1Under $2 million

ProMIS Neurosciences Inc.: Raise no. 1, Apr 2018

Investors in this round

18 investors had bought by the notice of May 3, 2018: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for ProMIS Neurosciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $3 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them, other: 5,783,861 Units at US$0.30 per Unit (comprised of one common share and one-half of one common share purchase warrant, exercisable into a share at C$0.48 until April 30, 2023, subject to acceleration)
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
$64,761
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Canada (Federal Level)

People named in the notice

  • Daniel E. Geffken · Executive Officer
  • Elliot Goldstein · Executive Officer, Director
  • Eugene Williams · Executive Officer, Director
  • Johanne Kaplan · Executive Officer
  • Neil Cashman · Executive Officer, Director
  • Anthony Giovinazzo · Director
  • Johannes Roth · Director
  • Patrick Kirwin · Director
  • Richard Gregory · Director
  • William Wyman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Noble Capital Markets, Inc. (CRD 15768) · Boca Raton, FloridaSold in FL, NJ, NV

Remarks in the notice

  • On fees: “Placement fees of US$64,761 representing 7% of the gross proceeds from the sale of Units to investors introduced by Noble Capital Markets Inc., which also received 215,871 warrants, exercisable at C$0.48 per share for five years.”
  • On the amounts: “Offering Amount equals price of Units(5783861 x US$0.3(C$0.375)/unit) plus exercise price of underlying Warrants(2891926 x C$0.48(US$0.384)/share).No guarantee that the Warrants, expiring 4/30/2023, will be exercised. Based on exchange rate of US$1:C$1.25”

Signed by Elliot Goldstein, CEO and President. Source: SEC Form D, newest notice filed May 3, 2018. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • ProMIS Neurosciences Inc. had no revenue when it filed its newest notice of a funding round (Oct 2022).

    SEC Form D (revenue range) · Oct 2022

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Oct 2022

Products and services#

No products or services of ProMIS Neurosciences Inc. are on record.

Investors#

1 named in official filings. Open an investor to see everything it has backed.

Investors in ProMIS Neurosciences Inc.
InvestorKindAmountRoundRoleSource
19 Promis TitlePersonnot statednot statedHeld preferred stock, 10% owner (Form 3, 2023)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 34 investors.

Largest shareholders today

Institutions holding Promis Neurosciences Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by ProMIS Neurosciences Inc.
NameRoleNamed in
Daniel T. GeffkenExecutive officerOct 2022
Gail M. FarfelExecutive officerOct 2022
Gavin T. MalenfantExecutive officerOct 2022
Larry M. AltstielExecutive officerOct 2022
Neil M. CashmanExecutive officerOct 2022
Daniel GeffkenExecutive officerSep 2021
Elliot GoldsteinExecutive officerSep 2021
Eugene WilliamsExecutive officerSep 2021
Johanne KaplanExecutive officerSep 2021
Neil CashmanExecutive officerSep 2021
Daniel E. GeffkenExecutive officerMar 2021
Steven PlotkinExecutive officerMar 2021
Eugene T. WilliamsDirectorOct 2022
Josh T. Mandel-BrehmDirectorOct 2022
Maggie T. ShafmasterDirectorOct 2022
Neil K. WarmaDirectorOct 2022
Neil M. CashmanDirectorOct 2022
Patrick T. KirwinDirectorOct 2022
Richard T. GregoryDirectorOct 2022
William K. WymanDirectorOct 2022
Eugene WilliamsDirectorSep 2021
Neil CashmanDirectorSep 2021
Patrick KirwinDirectorSep 2021
Richard GregoryDirectorSep 2021
William WymanDirectorSep 2021
Elliot GoldsteinDirectorMar 2021
Anthony GiovinazzoDirectorMay 2018
Johannes RothDirectorMay 2018

Went public since 2022. Its SEC number is that of a company listed on a stock exchange.